TLR9 and neoplasm: The immunological and resulting anti-tumor potential of EnanDIM®, including beneficial TME modulation, inhibition of tumor growth and induction of long-lasting tumor-specific memory, favors the EnanDIM® family of TLR9 agonists for further preclinical and clinical development as cancer immunotherapy for systemic and local administration.